Casirivimab/imdevimab - Regeneron Pharmaceuticals/Roche
Alternative Names: Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies - Regeneron Pharmaceuticals/Roche; Casirivimab and Imdevimab - Regeneron Pharmaceuticals/Roche; Casirivimab+Imdevimab - Regeneron Pharmaceuticals/Roche; REGEN-COV; REGEN-COV2; REGEN-COVTM; REGN COV2; REGN-10933+ REGN-10987; REGN10933-10987; RG 6413/RG 6412; Ronapreve; SARS-CoV-2 virus multi-antibody therapy - Regeneron Pharmaceuticals/RocheLatest Information Update: 28 Apr 2024
At a glance
- Originator Regeneron Pharmaceuticals
- Developer Chugai Pharmaceutical; Regeneron Pharmaceuticals; Roche; University of Oxford
- Class Antibodies; Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in Unknown (Parenteral)
- 03 Nov 2023 Pharmacokinetics data from a phase I/II/III trial in COVID-2019 infections presented at the 2023 American College of Clinical Pharmacology Annual Meeting (ACCP-2023).
- 10 Sep 2023 Pharmacokinetics data from a phase III trial in COVID-2019 infections presented in 2023 American College of Clinical Pharmacology Annual Meeting (ACCP-2023)